eISSN: 2299-0054
ISSN: 1895-4588
Videosurgery and Other Miniinvasive Techniques
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2023
vol. 18
 
Share:
Share:
General surgery
abstract:
Original paper

Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma

You-Bin Wang
1
,
Wei Zhang
2
,
Le Bao
1
,
Yun Lu
3
,
Jiao Hong
3

1.
Department of Interventional Radiology, Xuzhou Cancer Hospital, Xuzhou, China
2.
Department of Liver Disease, Daxing Hospital, Xi’an, China
3.
Department of Radiology, Xuzhou Central Hospital, Xuzhou, China
Videosurgery Miniinv 2023; 18 (4): 645–654
Online publish date: 2023/09/22
View full text Get citation
 
PlumX metrics:
Introduction
For patients diagnosed with hepatocellular carcinoma (HCC) not eligible for surgical tumor resection, transarterial chemoembolization (TACE) is commonly employed as a therapeutic strategy. After TACE is complete, a variety of other therapeutic approaches can be employed to improve patient overall survival (OS) and progression-free survival (PFS).

Aim
This study was developed with the goal of comparing the relative clinical efficacy and long-term outcomes observed in HCC patients who underwent combination TACE and radioactive seed insertion (RSI) treatment to those of patients who only underwent TACE treatment.

Material and methods
This retrospective analysis included a total of 80 patients with HCC who underwent treatment via TACE with (n = 39) or without (n = 41) RSI. Treatment responses and long-term outcomes in these two groups were compared with one another.

Results
The baseline characteristics of both groups were comparable. None of the patients experienced adverse complications related to treatment. Individuals in the combination treatment group experienced complete response (59.0% vs. 22.0%, p = 0.001) and total response (92.3% vs. 58.5%, p = 0.001) rates that were significantly better than those of patients that underwent TACE alone. Combination treatment was also associated with significant prolongation of patient PFS (13 vs. 7 months, p = 0.019) and OS (23 vs. 15 months, p = 0.005), with Cox regression analyses identifying combination treatment as a predictor of prolonged PFS and OS.

Conclusions
These data suggest that a combination of TACE and RSI can contribute to significant improvements in HCC patient therapeutic response rates, OS, and PFS relative to TACE alone.

keywords:

hepatocellular carcinoma, brachytherapy, transarterial chemoembolization

  
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.